VRDN — VIRIDIAN THERAPEUTICS INC

Ownership history in Bellevue Group AG  ·  9 quarters on record

This page tracks every 13F SEC filing in which Bellevue Group AG reported a position in VIRIDIAN THERAPEUTICS INC (VRDN). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
2.57% (2025 Q4)
Avg. % of fund
0.3%
First filed
2022 Q2
Last filed
2025 Q4
Quarters held
9
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 ADDED 4,358,527 +4,339,427 +22719.5% 2.57% $135.6M $31.12
2024 Q1 REDUCED 19,100 -10,900 -36.3% 0.01% $334K $17.51
2023 Q4 REDUCED 30,000 -33,770 -53.0% 0.01% $653K $21.78
2023 Q3 ADDED 63,770 +19,370 +43.6% 0.02% $978K $15.34
5 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    VRDN price (monthly, adj. close)

Other funds also holding VRDN

As of 2025 Q4 — sorted by position size

Fairmount Funds Management LLC 3Y 9.27% Elmind Capital, LP 7.89% Propel Bio Management, LLC 7.51% 5AM Venture Management, LLC 3Y 7.21% VR Adviser, LLC 3Y 5.97% Novo Holdings A/S 3Y 7Y 5.75% Rosalind Advisors, Inc. 4.92% Kopp Family Office, LLC 3Y 3.44% HighVista Strategies LLC 3Y 7Y 2.99% Kynam Capital Management, LP 3Y 2.92%
← Back to Bellevue Group AG Holdings